
|Videos|August 18, 2022
Current Standards of Care for Polycythemia Vera and Essential Thrombocytosis
Author(s)Naveen Pemmaraju, MD
Dr Naveen Pemmaraju discusses the current treatment standards for both polycythemia vera and essential thrombocythemia, highlighting the needs of high-risk patients.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Behind the FDA Approval: Isatuximab On-Body Injector Supports ‘Patient-Centric’ Priorities in Multiple Myeloma
2
Safusidenib Shows Durable Responses in IDH1-Mutant Glioma at 3-Year Follow-Up
3
De-Escalated Neoadjuvant HER2-Targeted Therapy Shows Durable 5-Year Survival
4
CheckMate 9LA Data Push Toward Dual Checkpoint Blockade in PD-L1–Negative NSCLC
5

























